Home » Authors » James Etheridge

Articles by James Etheridge

LibraGen Enters Research Deal With Sanofi-Aventis

Nov. 1, 2006

By James Etheridge

Innate Planning For IPO, Seeking €25M To €36M

Nov. 1, 2006

By James Etheridge

Cytheris' €24M Series B Round Should Fuel Company Into 2009

Nov. 1, 2006

By James Etheridge

Innate Planning For IPO, Seeking €25M To €36M

Nov. 1, 2006

By James Etheridge

No Abstract

LibraGen Enters Research Deal With Sanofi-Aventis

Nov. 1, 2006

By James Etheridge

Cytheris' €24M Series B Round Should Fuel Company Into 2009

Nov. 1, 2006

By James Etheridge

No Abstract

BioAlliance Pharma Receives Loramyc Marketing Approval

Oct. 18, 2006

By James Etheridge

BioAlliance Pharma Receives Loramyc Marketing Approval

Oct. 18, 2006

By James Etheridge

Innate Pharma Selects New Drug For Preclinical Program

Oct. 11, 2006

By James Etheridge

Faust Brings In €8M Bridge Financing, Aims For More

Oct. 11, 2006

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 13, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 13, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.